Skip to main content
    A

    Abbott Laboratories (ABT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.52
    -1.00 (-0.92%)

    Market Cap: $187.95B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Abbott Laboratories (ABT) Earnings: Report Dates and Results

    Updated Oct 21, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Abbott Laboratories (ABT) is expected to report earnings on Jan 20, 2027. In the quarter ended Sep 30, 2026, Abbott Laboratories reported EPS of $1.42, below the $1.43 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +6.39%

    Upcoming Estimates

    Reports Jan 20, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.65
    Range$1.60 - $1.73
    27 analysts
    Revenue Consensus
    $13.35B
    Range$12.88B - $14.05B
    27 analysts
    Reports Apr 14, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.23
    Range$1.20 - $1.28
    18 analysts
    EPS Revisions
    1
    13
    30d
    EPS Estimate DriftChange to current
    90d ago$1.29-4.4%
    60d ago$1.29-4.4%
    30d ago$1.29-4.4%
    7d ago$1.230.0%
    Current$1.23
    Revenue Consensus
    $12.57B
    Range$12.43B - $12.73B
    17 analysts

    Next Report

    ABT has an expected report date of Jan 20, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.0% above the $1.50 reported for the quarter ended Dec 31, 2025.

    ABT Earnings Call

    The latest ABT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ABT beat 29, missed 1 and matched 10. Revenue for the quarter ended Sep 30, 2026 was $13.01B, up 14.4% from $11.37B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.42$1.43$1.31 - $1.44-0.70%Miss+9.2%231 up, 1 downOct 21, 2026$13.01B
    Jun 30, 2026$1.31$1.28$1.26 - $1.29+2.34%Beat+4.0%230 up, 1 downJul 16, 2026$12.59B
    Mar 31, 2026$1.15$1.15$1.12 - $1.210.00%In line+5.5%240 up, 7 downApr 16, 2026$11.16B
    Dec 31, 2025$1.50$1.49$1.45 - $1.51+0.67%Beat+11.9%231 up, 1 downJan 22, 2026$11.46B
    Sep 30, 2025$1.30$1.30$1.28 - $1.330.00%In line+7.4%242 up, 2 downOct 15, 2025$11.37B
    Jun 30, 2025$1.26$1.26$1.14 - $1.300.00%In line+10.5%221 up, 0 downJul 17, 2025$11.14B
    Mar 31, 2025$1.09$1.07$1.05 - $1.09+1.87%Beat+11.2%203 up, 1 downApr 16, 2025$10.36B
    Dec 31, 2024$1.34$1.34$1.33 - $1.370.00%In line+12.6%202 up, 1 downJan 22, 2025$10.97B
    Sep 30, 2024$1.21$1.20$1.18 - $1.23+0.83%Beat+6.1%211 up, 1 downOct 16, 2024$10.63B
    Jun 30, 2024$1.14$1.10$1.09 - $1.12+3.64%Beat+5.6%201 up, 2 downJul 18, 2024$10.38B
    Mar 31, 2024$0.98$0.95$0.94 - $0.99+3.16%Beat-4.9%200 up, 1 downApr 17, 2024$9.96B
    Dec 31, 2023$1.19$1.19$1.18 - $1.210.00%In line+15.5%191 up, 0 downJan 24, 2024$10.24B
    Sep 30, 2023$1.14$1.10$1.06 - $1.12+3.64%Beat-0.9%192 up, 1 downOct 18, 2023$10.14B
    Jun 30, 2023$1.08$1.05$1.01 - $1.10+2.86%Beat-24.5%193 up, 0 downJul 20, 2023$9.98B
    Mar 31, 2023$1.03$0.99$0.96 - $1.02+4.04%Beat-40.5%192 up, 0 downApr 19, 2023$9.75B
    Dec 31, 2022$1.03$0.94$0.87 - $1.09+9.57%Beat-22.0%194 up, 0 downJan 25, 2023$10.09B
    Sep 30, 2022$1.15$0.94$0.84 - $1.10+22.34%Beat-17.9%204 up, 0 downOct 19, 2022$10.41B
    Jun 30, 2022$1.43$1.14$1.00 - $1.28+25.44%Beat+22.2%181 up, 1 downJul 20, 2022$11.26B
    Mar 31, 2022$1.73$1.46$1.32 - $1.51+18.49%Beat+31.1%191 up, 3 downApr 20, 2022$11.89B
    Dec 31, 2021$1.32$1.21$1.14 - $1.35+9.09%Beat-9.0%185 up, 0 downJan 26, 2022$11.47B
    Sep 30, 2021$1.40$0.95$0.90 - $1.17+47.37%Beat+42.9%20N/AOct 20, 2021$10.93B
    Jun 30, 2021$1.17$1.02$0.98 - $1.07+14.71%Beat+105.3%20N/AJul 22, 2021$10.22B
    Mar 31, 2021$1.32$1.27$1.11 - $1.43+3.94%Beat+103.1%20N/AApr 20, 2021$10.46B
    Dec 31, 2020$1.45$1.35$1.30 - $1.40+7.41%Beat+52.6%19N/AJan 27, 2021$10.70B
    Sep 30, 2020$0.98$0.91$0.84 - $0.98+7.69%Beat+16.7%19N/AOct 21, 2020$8.85B
    Jun 30, 2020$0.57$0.42$0.29 - $0.53+35.71%Beat-30.5%18N/AJul 16, 2020$7.33B
    Mar 31, 2020$0.65$0.61$0.17 - $0.69+6.56%Beat+3.2%14N/AApr 16, 2020$7.73B
    Dec 31, 2019$0.95$0.95$0.94 - $0.950.00%In line+17.3%17N/AJan 22, 2020$8.31B
    Sep 30, 2019$0.84$0.84$0.83 - $0.850.00%In line+12.0%18N/AOct 16, 2019$8.08B
    Jun 30, 2019$0.82$0.80$0.78 - $0.81+2.50%Beat+12.3%20N/AJul 17, 2019$7.98B
    Mar 31, 2019$0.63$0.62$0.60 - $0.63+1.61%Beat+6.8%20N/AApr 17, 2019$7.54B
    Dec 31, 2018$0.81$0.81$0.80 - $0.820.00%In line+9.5%21N/AJan 23, 2019$7.76B
    Sep 30, 2018$0.75$0.75$0.73 - $0.770.00%In line+13.6%19N/AOct 17, 2018$7.66B
    Jun 30, 2018$0.73$0.71$0.70 - $0.72+2.82%Beat+17.7%18N/AJul 18, 2018$7.77B
    Mar 31, 2018$0.59$0.58$0.57 - $0.59+1.72%Beat+22.9%18N/AApr 18, 2018$7.39B
    Dec 31, 2017$0.74$0.73$0.71 - $0.76+1.37%Beat+13.8%18N/AJan 24, 2018$7.59B
    Sep 30, 2017$0.66$0.65$0.64 - $0.66+1.54%Beat+11.9%18N/AOct 18, 2017$6.83B
    Jun 30, 2017$0.62$0.61$0.59 - $0.62+1.64%Beat+12.7%18N/AJul 20, 2017$6.64B
    Mar 31, 2017$0.48$0.43N/A+11.63%Beat+17.1%N/AN/AApr 19, 2017$6.33B
    Dec 31, 2016$0.65$0.65N/A0.00%In line+4.8%N/AN/AJan 25, 2017$5.33B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $5.15, up 10.3% from the year before. It was $2.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$5.15+10.3%
    Dec 31, 2024$4.67+5.2%
    Dec 31, 2023$4.44-16.9%
    Dec 31, 2022$5.34+2.5%
    Dec 31, 2021$5.21+42.7%
    Dec 31, 2020$3.65+12.7%
    Dec 31, 2019$3.24+12.5%
    Dec 31, 2018$2.88+15.2%
    Dec 31, 2017$2.50+13.6%
    Dec 31, 2016$2.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 12,000 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202611,54711
    2026Q2Jun 30, 20265,77512
    2026Q1Mar 31, 20267,41813
    2025Q4Dec 31, 202510,27612
    2025Q3Sep 30, 202510,17812
    2025Q2Jun 30, 20255,40013
    2025Q1Mar 31, 20258,85812
    2024Q4Dec 31, 20247,81913

    2026Q3 Earnings Call

    Opening remarks

    Mike Comilla Vice President, Investor Relations Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance, and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2025. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty, and without unreasonable effort, the timing and impact of certain items which could significantly impact Abbott's results in accordance with GAAP. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth. Our definition of comparable sales growth can be found on page 2 of our press release issued earlier today, and a reconciliation table containing the data needed to calculate comparable sales growth can be found on pages 16 and 17. With that, I will now turn the call over to Robert.

    Robert Ford Chairman and CEO Thanks, Mike. Today marks an important milestone in Abbott's history. Along with reporting our third quarter results, we announced our intention to separate our nutrition business into an independent, publicly traded company. This decision follows a comprehensive strategic review and reflects our strong belief that both Abbott and the nutrition business can create greater value and achieve their maximum potential as independent organizations. Abbott entered the nutrition business more than 60 years ago. Since that time, we built a strong foundation anchored by a talented global organization, iconic brands, scale, and established market leadership positions across the pediatric and adult nutrition categories. The nutrition market has evolved over time, with the pace of change accelerating significantly in recent years.

    Frequently Asked Questions About ABT

    When is Abbott Laboratories's next earnings date?

    Abbott Laboratories's next earnings report is expected for Jan 20, 2027.

    Did ABT beat earnings estimates last quarter?

    No. Abbott Laboratories reported EPS of $1.42 for the quarter ended Sep 30, 2026, below the $1.43 estimate by 0.70%.

    What EPS do analysts expect from ABT next quarter?

    The consensus EPS estimate for Abbott Laboratories for the quarter ending Dec 31, 2026 is $1.65 from 27 analysts, with estimates from $1.60 to $1.73.

    How often does ABT beat earnings estimates?

    Abbott Laboratories beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.52%.